DCTH Delcath stock news
On July 4, 2026, Delcath Systems Inc. (DCTH) announced the presentation of retrospective clinical data at the ESMO Breast Cancer Congress 2026. The study evaluated the use of the CHEMOSAT Hepatic Delivery System in 15 patients with liver--dominant metastatic breast cancer, reporting a 60% hepatic partial response rate among evaluable patients. Although 80% of subjects experienced Grade 3--4 post--procedural adverse events, primarily bone marrow suppression, the findings underscore the potential clinical utility of percutaneous hepatic perfusion (PHP) for expanded oncology indications beyond uveal melanoma.